PHARMACEUTICAL PREPARATIONS INCLUDING THOSE CONTAINING

Brand Owner (click to sort) Address Description
CARDACOR Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 PHARMACEUTICAL PREPARATIONS INCLUDING THOSE CONTAINING DILTIAZEM HYDROCHLORIDE FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS;
CARDACOR XT Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 PHARMACEUTICAL PREPARATIONS INCLUDING THOSE CONTAINING DILTIAZEM HYDROCHLORIDE FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDER;
CARTIA XT Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 PHARMACEUTICAL PREPARATIONS INCLUDING THOSE CONTAINING DILTIAZEM HYDROCHLORIDE FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS;
KETO XT Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 pharmaceutical preparations including those containing ketoprofen for use in the treatment of arthritis;
LOVASTAT XT Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 pharmaceutical preparations including those containing lovastatin for use in the treatment of cardiovascular disorders;
NIFED XT Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 pharmaceutical preparations including those containing nifedipine for use in the treatment of cardiovascular disorders;
PRAZOLE Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 PHARMACEUTICAL PREPARATIONS INCLUDING THOSE CONTAINING OMEPRAZOLE FOR USE IN THE TREATMENT OF DUODENAL ULCERS AND GASTROESOPHAGEAL REFLUX DISORDERS;
PRAZOLE XT Andrx Pharmaceuticals, Inc. 4955 Orange Drive Davie FL 33314 pharmaceutical preparations including those containing omeprazole for use in the treatment of duodenal ulcers and gastroesophageal reflux disorders;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.